Strides Pharma Science Limited — Investor Meet, 04-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Financial Performance: Strides Pharma Science reported strong results for the quarter, with a revenue increase of 17.3% year-over-year, amounting to INR 1,307 crore. Gross margins improved to 58.4%, with EBITDA rising 43% to INR 210 crore and an EBITDA margin of 18.2%. The profit after tax (PAT) for the quarter was INR 90 crore, leading to a reported EPS of INR 9.56. The company highlighted a clean financial picture post-demerger of its high-margin soft gelatin business.

Future Outlook and Growth Drivers: Management emphasized a sustained focus on growth, aiming for revenue targets of $275 million to $290 million in the U.S. by FY '25. Key growth drivers include successful launches from the acquired Endo portfolio and anticipated approvals for new products. They remain optimistic about achieving 12-15% revenue growth in the upcoming years while maintaining efforts to enhance operational efficiencies.

Order Book and Operational Updates: Strides reported five product approvals and four product launches in the U.S. this quarter, contributing to a total of 71 commercialized products. Further expansion is expected in both regulated and growth markets, noting 32.4% YOY growth in Growth and Access Markets.

Analyst Q&A Insights: Analysts raised concerns regarding margin expectations and growth sustainability post-demerger. Management reassured stakeholders about strong operational cash generation and the ability to meet guidance. They also faced inquiries regarding competitive threats in the U.S. market, affirming that while market dynamics remain challenging, price erosion from previous years has moderated.

Market or Regulatory Updates: Management discussed ongoing regulatory processes and product launches, with expectations for growth in the Other Regulated Markets after delays due to partner approvals. The assessment of market conditions also included a positive outlook on operational compliance and product margins.

Strategic Focus Areas: Strides is concentrating on leveraging its high-margin opportunities within its product portfolio while continuing to invest in innovation and talent acquisition. The focus on ESG has yielded a commendable score, reflecting commitment to sustainability.

Investor Insight: The robust financial health, combined with a strategic focus on core business segments and operational efficiency, suggests a favorable position moving forward, indicating a potential for a ‘buy’ stance, considering future growth prospects and manageable risks.